Comprehensive SDSU/UCSD Cancer Center Partnership 1 of 2

描述(申请人提供)：生物技术和生物化学的重大进步导致了大量基于多肽和蛋白质的癌症疫苗的发现。然而，由于疫苗的生物利用度受到酶降解的限制，开发合适和有效的载体系统仍然是一个重大挑战。我们最近开发了几种基于天然和修饰的Survivin衍生多肽的前列腺癌新疫苗。我们建议将Survivin衍生的多肽疫苗封装到我们新开发的针对树突状细胞上的甘露糖受体的纳米颗粒中。在纳米颗粒配方中加入甘露糖或其某些衍生物有望增强活性抗原的传递，这是这一试点项目在概念上的重大进展。我们认为，这种新型疫苗将诱导针对前列腺癌的有效和特异的免疫反应。由于Survivin在所有前列腺癌中都高度表达，这种新的纳米颗粒疫苗策略可能会有重要的临床应用。这种方法可能为前列腺癌的免疫治疗提供一条潜在的途径，因为到目前为止已经描述了许多其他前列腺癌相关抗原。

DESCRIPTION (provided by applicant): Significant advances in biotechnology and biochemistry have led to the discovery of a large number of cancer vaccines based on peptides and proteins. However, the development of suitable and efficient carrier systems remains a major challenge since the vaccine bioavailability is limited by enzymatic degradation. We developed recently several promising new vaccines for prostate cancer based on natural and modified survivin-derived peptides. We propose to encapsulate the survivin-derived peptide vaccines into our newly developed nanoparticles targeted to the mannose receptors on the dendritic cells. The inclusion of mannose or some of its derivatives in the nanoparticle formulation is expected to enhance delivery of active antigen and is the major conceptual advance of this pilot project. We suggest that this novel vaccine will induce potent and specific immune responses against prostate cancer. Because survivin is highly expressed in all prostate cancer, this new nanoparticle-vaccine strategy may have important clinical applications. This approach may provide a potential avenue for immunotherapy of prostate cancer, as many other prostate cancer-associated antigens have been described to date.